anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A cosmetic kit comprises at least two compositions, which are packaged separately. The kit comprises silicone compounds (X1), silicone compounds (Y1) and optionally catalysts, with the provision that the compounds (X1), (Y1) and the catalyst when present are not simultaneously in one of the compositions. The compounds (X1) and (Y1) are reacting together by a hydrosilylation reaction when the catalyst is present or by condensation reaction, when they are brought into contact with one another. At least one of the first and second compositions comprising at least one glossy oil. A cosmetic kit comprises at least two compositions, which are packaged separately. The kit comprises at least one silicone compound (X1), at least one silicone compound (Y1) and optionally at least one catalyst, with the provision that the compounds (X1), (Y1) and the catalyst when present are not simultaneously in one of the compositions. The compounds (X1) and (Y1) are reacting together by a hydrosilylation reaction when the catalyst is present or by condensation reaction, when they are brought into contact with one another. At least one of the first and second composition comprising at least one glossy oil. The compounds (X1) and (Y1) and the glossy oil, and their respective amounts, are such that the average gloss of a deposit comprising the two compositions, measured at 60[deg] , is >= 60 out of 100. An independent claim is included for cosmetic method involving the application to the keratin materials, via at least one composition, of the compounds (X1) and (Y1) of which at least one is a silicone compound, and of the optional catalyst, the compounds X1 and Y1 reacting together by hydrosilylation when the catalyst is present or by condensation, when contacted with one another, and of at least one glossy oil, the compounds X1 and Y1 and the ester oil, and their respective amounts, are such that the average gloss of a deposit comprising X1, Y1 and the glossy oil, measured at 60[deg] , is >= 60 out of 100.
After an intubating dose of 0.08 to 0.1 mg/kg, a continuous infusion of 1 mcg/kg/min can be initiated approximately 20 to 40 minutes later. Infusion of vecuronium bromide should be initiated only after early evidence of spontaneous recovery from the bolus dose. Long-term intravenous infusion to support mechanical ventilation in the intensive care unit has not been studied sufficiently to support dosage recommendations. (see PRECAUTIONS, Long Term Use in ICU).

The infusion of vecuronium bromide should be individualized for each patient. The rate of administration should be adjusted according to the patient's twitch response as determined by peripheral nerve stimulation. An initial rate of 1 mcg/kg/min is recommended, with the rate of the infusion adjusted thereafter to maintain a 90% suppression of twitch response. Average infusion rates may range from 0.8 to 1.2 mcg/kg/min.

Inhalation anesthetics, particularly enflurane and isoflurane may enhance the neuromuscular blocking action of nondepolarizing muscle relaxants. In the presence of steady-state concentrations of enflurane or isoflurane, it may be necessary to reduce the rate of infusion 25% to 60%, 45 to 60 minutes after the intubating dose. Under halothane anesthesia it may not be necessary to reduce the rate of infusion.

Spontaneous recovery and reversal of neuromuscular blockade following discontinuation of vecuronium bromide infusion may be expected to proceed at rates comparable to that following a single bolus dose (see CLINICAL PHARMACOLOGY).

Infusion solutions of vecuronium bromide can be prepared by adding vecuronium bromide with an appropriate infusion solution such as Dextrose 5% Injection, Sodium Chloride 0.9% Injection, Dextrose 5% and Sodium Chloride 0.9% Injection, or Lactated Ringer's Injection.

Unused portions of infusion solutions should be discarded.

Infusion rates of vecuronium bromide can be individualized for each patient using the following table:
A traditional Chinese medicine formula for treating onychomycosis is characterized by comprising the following ingredients: 40 g of golden larch bark, 30 g of cortex phellodendri, 20 g of garden balsam stem, 30 g of crepis napifera, 20 g of single clove garlic and 2000 ml of white vinegar. Preparation and medication: mixing the above five medicinal materials, adding 2000 ml of white vinegar, decocting and taking a decoction so as to obtain a liquid medicine for treating onychomycosis. Disease fingernails are immersed with the liquid medicine for 15-30 min every night. Use frequency of the liquid medicine is generally 15 times. The problem that present drug therapy of onychomycosis has great side-effect is solved. The traditional Chinese medicine formula of the invention is suitable for treatment of onychomycosis.
Patients randomized to the study medication have to take bromocriptine orally for the first 14 days at a dose of 5 mg/day (= 2 tablets, 1 in morning, 1 in the evening). From day 15 to day 56 they will take a dose of 2.5 mg (= 1 tablet) orally in the evening. The duration of the intervention is 8 weeks, thereafter the patients continue to be observed in the follow-up part of the study up to month 6. The study medication is taken on top of standard therapy for heart failure. Part of this therapy are ACE inhibitors. ACE inhibitors are potentially harmful for the baby when getting into the breast milk, as bromocriptine stops milk production, no additional drug is needed.
BACKGROUND: The impact of lower urinary tract symptoms (LUTS) on the quality of life of patients with benign prostatic hyperplasia (BPH) has been rarely reported. Additionally, the challenges faced by these patients in seeking medical care have often been overlooked. In order to explore the personal struggles caused by LUTS and the difficulties or barriers experienced by Chinese patients with BPH when seeking help, we conducted a qualitative interview study.
METHODS: Qualitative interviews were conducted among 46 patients with BPH who were hospitalized in three tertiary hospitals in China from July 2021 to November 2022. Grounded theory was adopted as the methodology for the qualitative study. After obtaining written informed consent from the study participants, semi-structured interviews were conducted according to the question guidelines. The interview process was audio-recorded; subsequently, the recordings were transcribed, coded, and thematically analyzed.
RESULTS: The difficulties faced by Chinese patients with BPH were classified into seven main themes: (i) disturbed life, (ii) mental burden, (iii) disease cognition and communication, (iv) delayed treatment, (v) medication status, (vi) hospital visits barriers, and (vii) medical insurance issues. Further, each theme was subdivided into 2-5 sub-themes.
CONCLUSIONS: LUTS have a certain effect on the life and spirit of patients with BPH. These patients face different degrees of difficulties in treatment and hospital visits. Therefore, better healthcare systems and additional social support are crucial for improving the current plight of these patients.
This DMA persistence food trial provides critical complimentary data to the ongoing efficacy food trials of SBD111 and SBD121 medical foods. While the SBD111 and SBD121 medical food products have been tested in multiple preclinical studies, GLP-Toxicity studies in Rats, and ongoing safety and efficacy trials, no study has yet examined how quickly these DMAs become detectable/active in human stool samples or the rate they clear from human stool following treatment cessation. The data provided by this study could inform the interpretation efficacy trial data with regard to subject adherence.

Objectives The primary goal of this study is to evaluate the prevalence and persistence of SBD111 and SBD121 medical foods, two novel combinations of probiotics and prebiotic dietary fibers, over time in stool samples. We will determine the effect of these Defined Microbial Assemblages (DMAs) on fecal microbiota composition and functional potential, as well as the duration of SBD111 and SBD121 product persistence in the gastrointestinal tract. DMAs will be administered for 7 days, and stool samples will be collected during DMA administration and up to 28 days post DMA cessation for microbial DNA extraction. Fecal microbial DNA will be subjected to qPCR and high throughput shotgun sequencing to determine the presence and amount of DMA microbes that are present before, during, and after DMA administration. We will also use the resulting shotgun sequencing data to determine whether any taxonomic shifts or functional changes occur in response to DMA administration and/or cessation. Finally, as an exploratory measure, we will attempt to isolate live DMA microbes from participants' fecal samples using microbiological techniques.
Forensic taphonomy, the study of post-mortem processes, is pivotal in modern forensic science. This short communication illuminates limitations in traditional 2D imaging, specifically digital photographs, within forensic taphonomy, and highlights the vast potential of 3D modeling techniques. Drawing from a recent study in Hawaii's tropical savanna, we unveil disparities between real-time observations and 2D photographs when assessing decomposition, emphasizing the importance of scoring method selection and the need to scrutinize 2D imaging's accuracy in forensic taphonomy. Conversely, 3D modeling techniques, an emerging powerhouse in forensic science, offer multidimensional data, including volume, surface area, and spatial relationships, allowing for comprehensive and precise representation of decomposition dynamics. Despite concerns about texture quality, 3D models yield objective data amenable to analysis by multiple experts, thus minimizing subjectivity and augmenting the reliability of forensic assessments. The potential for 3D modeling to bridge the gap between 2D imaging and real-time decomposition requires tailored methodologies. Future research should focus on standardizing protocols and fostering collaboration among forensic experts, technologists, and researchers to unleash 3D technology's full potential in advancing forensic taphonomy.
Women with stage 2 to 4 uterine prolapse. BMI from ≤ 35 kg\\m2. Women of any parity including nulliparas will be included. Age of female patients ranges from 20 to 40 years.
Subjects will receive a combined approach using MAT and LAT. LAT will be administered prior to the application of MAT on the selected auricular points, which would be implemented similar to the procedures in treatment arm 1 and 2.
The present invention relates to a natural composition effective for preventing and treating rheumatoid arthritis, and more specifically, to a natural composition effective for preventing and treating rheumatoid arthritis, using a composition extracted from Astragalus membranaceus, Sinomenium acutum (Thunb.) Rehder et Wilson, Aconitum carmichaeli Debx root, achyranthes, and Clematis mandshurica Maximowicz. Additionally, the present invention provides a composition effective for preventing and treating rheumatoid arthritis, extracted from a mixture of Astragalus membranaceus, Sinomenium acutum (Thunb.) Rehder et Wilson, Aconitum carmichaeli Debx root, achyranthes, and Clematis mandshurica Maximowicz, Atractylodis Rhizoma alba, Zingiber officinale Roscoe, jujube, and licorice. Additionally, the present invention provides a composition effective for preventing and treating rheumatoid arthritis, which is extracted from a mixture comprising: 100 parts by weight of Astragalus membranaceus; 70-100 parts by weight of Sinomenium acutum (Thunb.) Rehder et Wilson; 70-100 parts by weight of Aconitum carmichaeli Debx root; 50-80 parts by weight of achyranthes; 50-80 parts by weight of Clematis mandshurica Maximowicz; 50-80 parts by weight of Atractylodis Rhizoma alba; 50-80 parts by weight of Zingiber officinale Roscoe; 50-80 parts by weight of jujube; and 10-40 parts by weight of licorice. Additionally, the present invention provides a pharmaceutical composition comprising a composition effective for preventing and treating rheumatoid arthritis.
BACKGROUND: The Choosing Wisely® (CW) campaign recommended de-implementation of surgical management of axillary nodes in specified patients. This study aimed to assess trends in the application of CW guidelines for lymph node (LN) surgery in males with breast cancer.
METHODS: The National Cancer Database was queried for males diagnosed with breast cancer from 2017 to 2020. Patients were categorized into two cohorts based on CW criteria. Cohort 1 included all T1-2, clinically node-negative patients who underwent breast-conserving therapy and with ≤ 2 positive nodes, and Cohort 2 included all T1-2, node-negative, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative patients aged ≥ 70 years. In Cohort 1, patients who underwent sentinel LN biopsy (SLNB) alone were compared with axillary LN dissection (ALND) or no LN surgery, while in Cohort 2, patients who underwent LN surgery were compared with those with no LN surgery.
RESULTS: Of 617 patients who met the criteria for Cohort 1, 73.1% underwent SLNB alone compared with ALND (11.8%) or no LN surgery (15.1%). Those who received SLNB alone were younger (65 vs. 68 vs. 73 years; p < 0.001). The annual proportion of males who underwent SLNB alone remained stable from 2017 to 2020. Overall, 1565 patients met the criteria for Cohort 2, and 84.9% received LN surgery. LN surgery was omitted in older patients (81 vs. 77; p < 0.001). The proportion of elderly males with early-stage breast cancer who underwent LN surgery increased from 2017 to 2020.
CONCLUSION: This study demonstrates that CW recommendations are not being routinely applied to males. These findings reinforce the need for additional studies and subsequent recommendations for optimal application of axillary surgery de-implementation for males diagnosed with breast cancer.
<P>PROBLEM TO BE SOLVED: To provide a new percutaneous absorbefacient improving the absorption of a medicine through the skin when the medicine is applied as an external agent.  <P>SOLUTION: This percutaneous absorbefacient contains a fruit of Evodia rutaecarpa or an extract thereof. The percutaneous absorbefacient of a non- steroid antiinflammatory agent contains the fruit of the Evodia rutaecarpa or the extract thereof. The percutaneous absorbefacient of an acidic antiinflammatory agent contains the fruit of the Evodia rutaecarpa or the extract thereof. The percutaneous absorbefacient of an indole acetate-based antiinflammatory agent contains the fruit of the Evodia rutaecarpa or the extract thereof. The percutaneous absorbefacient of indomethacin, sulindac and acemetacin contains the fruit of the Evodia rutaecarpa or the extract thereof.  <P>COPYRIGHT: (C)2003,JPO
Although a chronic total occlusion (CTO) in the setting of an acute coronary syndrome is associated with greater risk, the prognosis of patients with a CTO and stable coronary artery disease (CAD) remains unknown. This study aimed to investigate adverse event rates in patients with stable CAD with and without a CTO. In 3,597 patients with stable CAD (>50% coronary luminal stenosis) who underwent cardiac catheterization, all-cause mortality, cardiovascular mortality, and the composite major adverse cardiac event (MACE) rates for cardiovascular death, myocardial infarction, and heart failure hospitalization were evaluated. Cox proportional hazards and Fine and Gray subdistribution hazard models were used to compare event-free survival in patient subsets after adjustment for covariates. Event rates were higher in patients with CTOs than in those without CTOs after adjusting for demographic and clinical characteristics (cardiovascular death hazard ratio [HR] 1.29, 95% confidence interval [CI] 1.05 to 1.57, p = 0.012). Patients with CTO revascularization had lower event rates than those of patients without CTO revascularization (cardiovascular death HR 0.43, CI 0.26 to 0.70, p = 0.001). Those with nonrevascularized CTOs were at particularly great risk when compared with those without CTO (cardiovascular death HR 1.52, CI 1.25 to 1.84, p <0.001). Moreover, those with revascularized CTOs had similar event rates to those of patients with CAD without CTOs. Patients with CTO have higher rates of adverse cardiovascular events than those of patients with significant CAD without CTO. This risk is greatest in patients with nonrevascularized CTO.
Antibody mediated killing of cancer cells is an effective approach to treat cancer. Antibodies generated in mice, upon immunization with lung adenocarcinoma cells, are screened for cytotoxicity against a variety of cancer cell lines as the endpomt. An anti-cancer cytotoxic monoclonal antibody is isolated, produced by the hyb.pi.udoma AR92A271.7 deposited with IDAC as Accession Number 290507-04, which is cytotoxic to a lung cancer cell line and reduces tumor burden in an animal model of human lung cancer.  The monoclonal antibody also binds to several cancer cell lines. There is low, but detectable, binding of the monoclonal antibody to a non-cancer cell line, however, cytotoxicity is not induced in this non-cancer cell line. This monoclonal antibody can be used to aid staging and diagnosis of cancer, and in the treatment of primary tumors and tumor metastases. This cytotoxic monoclonal antibody can also be used to deliver toxins, enzymes, radioactive compounds and hematogenous cells to cancer cells, to further aid reduction of tumor burden.
The expression of metastasis tumor-associated protein 2 (MTA2) and protein tyrosine kinase 7 (PTK7) is associated with hepatocellular carcinoma (HCC) progression. However, the functional effect and mechanism through which MTA2 regulates PTK7-mediated HCC progression remains unclear. Here, we found that MTA2 knockdown significantly down-regulated PTK7 expression in HCC cells (SK-Hep-1 and PLC/PRF/5). Data from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases show that the PTK7 expression level was higher in HCC tissues than in normal liver tissues. In HCC patients, the PTK7 expression level clearly correlated with tumor stage and grade, lower overall survival (OS) correlated positively with MTA2 level, and PTK7 expression acted as a downstream factor for MTA2 expression. In addition, matrix metalloproteinase 7 (MMP7) expression was closely regulated by PTK7, and the mRNA and protein expression levels of MTA2 and PTK7 correlated positively with lower OS. MMP7 downregulation by PTK7 knockdown clearly decreased the migration and invasion abilities of HCC cells. In HCC cells, recombinant human MMP7 reversed the PTK7 knockdown-induced suppression of migration and invasion. Furthermore, deactivation of FAK using siFAK or FAK inhibitor (PF-573228, PF) synergistically contributed to PTK7 knockdown-inhibited FAK activity, MMP7 expression, and the migration and invasion abilities of HCC cells. Collectively, our findings show that PTK7 mediates HCC progression by regulating the MTA2-FAK-MMP7 axis and may be a diagnostic value for HCC patients.
A heterocyclic compound represented by the general formula (V) (wherein R1b represents substituted C6-10 aryl, etc.; Ta represents a single bond, C1-6 alkyl, -CH2O-, etc.; X and Y are the same or different and each represents optionally substituted nitrogen, etc.; the broken lines each indicates a single bond or double bond; Za represents nitrogen or CH; W represents a single bond, oxygen, etc.; and Q represents an optionally substituted C6-10 aryl or optionally substituted aromatic heterocyclic group) or a salt of the compound. The compound and salt have excellent tyrosin kinase inhibitory activity. Also provided is a medicinal composition containing the heterocyclic compound or salt.
Cancer-related anorexia-cachexia syndrome (CACS) is a debilitating condition afflicting up to 80% of advanced-stage cancer patients. Characterized by progressive weight loss, muscle wasting, and metabolic abnormalities, CACS significantly compromises patients' quality of life and treatment outcomes. This comprehensive review navigates through its intricate physiopathology, elucidating its stages and diagnostic methodologies. CACS manifests in three distinct stages: pre-cachexia, established cachexia, and refractory cachexia. Early detection is pivotal for effective intervention and is facilitated by screening tools, complemented by nutritional assessments and professional evaluations. The diagnostic process unravels the complex interplay of metabolic dysregulation and tumor-induced factors contributing to CACS. Management strategies, tailored to individual patient profiles, encompass a spectrum of nutritional interventions. These include dietary counseling, oral nutritional supplements, and, when necessary, enteral nutrition and a judicious use of parenteral nutrition. Specific recommendations for caloric intake, protein requirements, and essential nutrients address the unique challenges posed by CACS. While pharmacological agents like megestrol acetate may be considered, their use requires careful evaluation of potential risks. At its core, this review underscores the imperative for a holistic and personalized approach to managing CACS, integrating nutritional interventions and pharmacological strategies based on a nuanced understanding of patient's condition.
To report SUSPECTED ADVERSE REACTIONS, contact LGM Pharma Solutions at 1-877-288-1495 or complaints@lgmpharma.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 

Adverse reaction information was derived from blinded-controlled and open-labeled clinical trials and from worldwide marketing experience. In the description below, rates of the more common events (greater than 1%) and many of the less common events (less than 1%) represent results of U.S. clinical studies.

Of the 1,677 patients who received nabumetone during U.S. clinical trials, 1,524 were treated for at least 1 month, 1,327 for at least 3 months, 929 for at least a year, and 750 for at least 2 years. More than 300 patients have been treated for 5 years or longer.

The most frequently reported adverse reactions were related to the gastrointestinal tract and included diarrhea, dyspepsia, and abdominal pain.
Before starting the motivational interviews, pre-test data will be obtained by applying the "Personal Information Form", "Insufficient Milk Perception Scale" and "Breastfeeding Motivation Scale" to the mothers in the intervention group. Afterwards, a sample of the mothers' saliva will be taken to measure their cortisol levels. A total of 4 sessions of motivational interviews will be held for infertile women, 1 session per week for four weeks. At the end of four weeks, post-test data will be obtained by applying the "Insufficient Milk Perception Scale" and "Breastfeeding Motivation Scale". A sample of the mothers' saliva will be taken to measure cortisol levels again.
PURPOSE:To provide a technology for making fish-and-shellfish peptides represented by mackerel peptide odorless or virtually odorless, and to provide an external or internal preparation incorporated with the resultant odorless or low-odoriferous component. CONSTITUTION:Water is added to fish-and-shellfish peptides obtained by enzymatic chemical modification of fish-and-shellfish proteins such as of mackerel followed by mixing under agitation and then conducting centrifugation, and the resulting supernatant is separated and then either dialyzed or put to ultrafiltration to eliminate low-molecular weight components, thus obtaining the odorless or low-odoriferous component 600-10000 in molecular weight. The above centrifugation and dialysis or ultrafiltration is made at <=15 deg.C. After the dialysis or ultrafiltration, purification may be made using an adsorbent. The other external preparation (e.g. cosmetic, quasidrug) or internal preparation (e.g. beverage, food, medicine) can be obtained by incorporating the original preparation with the above odorless or low-odoriferous component.